Cancer name Triple Negative Breast Cancer
Cancer Type BRCA
Immunotherapy type Immune Checkpoint Therapy;Immunostimulant OR Targeting Therapy
Treatment anti–PD-1 ab
Drugstatus NA
Drugbank ID NA
Checkpoints PD-L1
Signature Type Cell
Signature IFNγ+ CD8+ T Cell
Official Symbol NA
Mode of action CE_D_UP
Description for ‘mode of action’：the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation)，Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental mouse model
Description Analysis of the lymphocyte population in the lungs of these mice revealed that the combination therapy significantly increased the number of tumor cell-specific IFNγ-producing CD8+ T cells compared to poly(I:C) (P > 0.05) . This increase in CD8+ T-cell activity offers some rationale into the effectiveness of combining poly(I:C) and anti–PD-1 therapy.
PMID 28848054
Title Neoadjuvant Interferons: Critical for Effective PD-1-Based Immunotherapy in TNBC